Court Finds United Therapeutics' Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million

Core Viewpoint - Liquidia Corporation has achieved a significant legal victory against United Therapeutics, with the court ruling that United Therapeutics' interference with the launch of generic Treprostinil Injection resulted in losses exceeding $137 million for Liquidia [1][3]. Group 1: Legal Proceedings - The United States District Court for the District of New Jersey found United Therapeutics liable for its actions that interfered with the launch of generic Treprostinil Injection, which is manufactured by Sandoz Inc. [1][2] - Liquidia PAH and Sandoz filed a lawsuit in April 2019, alleging violations of the Sherman Antitrust Act and other unfair competition statutes by United Therapeutics [2][3]. - The court's decision determined that damages caused by United Therapeutics' breach of contract exceeded $137 million, although the final damage award is still pending [3]. Group 2: Financial Implications - Under the agreement between Sandoz and Liquidia PAH, any proceeds from the litigation will be split evenly between the two companies [4]. - Liquidia PAH has entered into litigation finance agreements with Henderson SPV, LLC and PBM RG Holdings, LLC, meaning that any net proceeds from the damage award will be distributed to these parties, leaving Liquidia PAH with no retained proceeds [4]. Group 3: Product Information - Treprostinil Injection is the first-to-file, fully substitutable generic version of treprostinil for parenteral administration, offering the same active ingredients and dosage forms as the branded drug Remodulin® but at a lower price [5]. - Liquidia PAH, in partnership with Sandoz, promotes the appropriate use of Treprostinil Injection for treating pulmonary arterial hypertension (PAH) in the United States [5][6]. Group 4: Company Overview - Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, with a current emphasis on pulmonary hypertension and applications of its proprietary PRINT® Technology [6]. - The company is also developing other formulations of treprostinil, including YUTREPIA™ and L606, while marketing generic Treprostinil Injection [6].